BACKGROUND: Patients with colorectal liver metastases (CLM) are increasingly treated with preoperative chemotherapy. Chemotherapy associated liver injury is associated with postoperative hepatic insufficiency (PHI) and mortality. The adequate minimum future liver remnant (FLR) volume in patients treated with extensive chemotherapy remains unknown. METHODS: All patients with standardized FLR > 20 %, who underwent extended right hepatectomy for CLM from 1993-2011, were divided into three cohorts by chemotherapy duration: no chemotherapy (NC, n = 30), short duration (SD, ≤12 weeks, n = 78), long duration (LD, >12 weeks, n = 86). PHI and mortality were compared by using uni-/multivariate analyses. Optimal FLR for LD chemotherapy was determined using a minimum p-value approach. RESULTS: A total of 194 patients met inclusion criteria. LD chemotherapy was significantly associated with PHI (NC + SD 3.7 vs. LD 16.3%, p = 0.006). Ninety-day mortality rates were 0 % in NC, 1.3 % in SD, and 2.3% in LD patients, respectively (p = 0.95). In patients with FLR > 30 %, PHI occurred in only two patients (both LD, 2/20, 10 %), but all patients with FLR > 30 % survived. The best cutoff of FLR for preventing PHI after chemotherapy >12 weeks was estimated as >30 %. Both LD chemotherapy (odds ratio [OR] 5.4, p = 0.004) and FLR ≤ 30 % (OR 6.3, p = 0.019) were independent predictors of PHI. CONCLUSIONS: Preoperative chemotherapy >12 weeks increases the risk of PHI after extended right hepatectomy. In patients treated with long-duration chemotherapy, FLR > 30 % reduces the rate of PHI and may provide enough functional reserve for clinical rescue if PHI develops.
BACKGROUND:Patients with colorectal liver metastases (CLM) are increasingly treated with preoperative chemotherapy. Chemotherapy associated liver injury is associated with postoperative hepatic insufficiency (PHI) and mortality. The adequate minimum future liver remnant (FLR) volume in patients treated with extensive chemotherapy remains unknown. METHODS: All patients with standardized FLR > 20 %, who underwent extended right hepatectomy for CLM from 1993-2011, were divided into three cohorts by chemotherapy duration: no chemotherapy (NC, n = 30), short duration (SD, ≤12 weeks, n = 78), long duration (LD, >12 weeks, n = 86). PHI and mortality were compared by using uni-/multivariate analyses. Optimal FLR for LD chemotherapy was determined using a minimum p-value approach. RESULTS: A total of 194 patients met inclusion criteria. LD chemotherapy was significantly associated with PHI (NC + SD 3.7 vs. LD 16.3%, p = 0.006). Ninety-day mortality rates were 0 % in NC, 1.3 % in SD, and 2.3% in LDpatients, respectively (p = 0.95). In patients with FLR > 30 %, PHI occurred in only two patients (both LD, 2/20, 10 %), but all patients with FLR > 30 % survived. The best cutoff of FLR for preventing PHI after chemotherapy >12 weeks was estimated as >30 %. Both LD chemotherapy (odds ratio [OR] 5.4, p = 0.004) and FLR ≤ 30 % (OR 6.3, p = 0.019) were independent predictors of PHI. CONCLUSIONS: Preoperative chemotherapy >12 weeks increases the risk of PHI after extended right hepatectomy. In patients treated with long-duration chemotherapy, FLR > 30 % reduces the rate of PHI and may provide enough functional reserve for clinical rescue if PHI develops.
Authors: Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: George A Poultsides; Fei Bao; Elliot L Servais; Tina Hernandez-Boussard; Ronald P DeMatteo; Peter J Allen; Yuman Fong; Nancy E Kemeny; Leonard B Saltz; David S Klimstra; William R Jarnagin; Jinru Shia; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2012-04-03 Impact factor: 5.344
Authors: Yoji Kishi; Daria Zorzi; Carlo M Contreras; Dipen M Maru; Scott Kopetz; Dario Ribero; Manuela Motta; Nicoletta Ravarino; Mauro Risio; Steven A Curley; Eddie K Abdalla; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2010-06-22 Impact factor: 5.344
Authors: Mechteld C de Jong; Carlo Pulitano; Dario Ribero; Jennifer Strub; Gilles Mentha; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Martin Palavecino; Yoji Kishi; Yun S Chun; David L Brown; Vijaya N R Gottumukkala; Benjamin Lichtiger; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Surgery Date: 2009-09-06 Impact factor: 3.982
Authors: Daria Zorzi; Yun Shin Chun; David C Madoff; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2008-07-18 Impact factor: 5.344
Authors: Junichi Shindoh; Ching-Wei D Tzeng; Thomas A Aloia; Steven A Curley; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2013-10-16 Impact factor: 3.452
Authors: Ching-Wei D Tzeng; Amanda B Cooper; Jean-Nicolas Vauthey; Steven A Curley; Thomas A Aloia Journal: HPB (Oxford) Date: 2013-08-26 Impact factor: 3.647
Authors: Kristoffer W Brudvik; Yoshihiro Mise; Claudius Conrad; Giuseppe Zimmitti; Thomas A Aloia; Jean-Nicolas Vauthey Journal: J Am Coll Surg Date: 2015-02-28 Impact factor: 6.113